Literature DB >> 31385967

Acute care in glioblastoma: the burden and the consequences.

Andrea Wasilewski1, Jennifer Serventi1, Lily Kamalyan1, Thomas Wychowski1, Nimish Mohile1.   

Abstract

BACKGROUND: The utilization of inpatient medical services by patients with glioblastoma (GBM) is not well studied. We sought to describe causes, frequency, and outcomes of acute care visits in GBM.
METHODS: We conducted a retrospective study of 158 GBM patients at the University of Rochester over 5 years. Electronic medical records were reviewed to identify all local and outside acute care visits. Acute care visits were defined as any encounter resulting in an emergency department visit or inpatient admission.
RESULTS: Seventy-one percent (112/158) of GBM patients had 235 acute care visits corresponding to 163 hospitalizations (69%) and 72 emergency department visits (31%). Sixty-three percent of patients had multiple visits. Admission diagnoses were seizure (33%), neurosurgical procedure (15%), infection (12%), focal neurologic symptoms (9%), and venous thromboembolism (VTE, 9%). Forty-six patients had 1 or more visits for seizures. Median time to first acute care visit was 65.6 days and 22% of patients had an acute care visit within 30 days of diagnosis. Median length of stay was 5 days. Thirty-five percent of admitted patients were discharged home; 62% required a higher level of care than prior to admission (23% were discharged home with services, 17% to a nursing facility, 16% to hospice, 6% to acute rehab) and 3% died. Thirty-eight percent of patients had ACV within 30 days of death. Median survival was 14 months for patients who had acute care visits and 22.2 months for patients who did not.
CONCLUSION: The majority of GBM patients utilize acute care, most commonly for seizures. The high number of emergency department visits, short length of stay, and many patients discharged home suggest that some acute care visits may be avoidable.

Entities:  

Keywords:  glioblastoma; health services; neuro-oncology; palliative care; seizures

Year:  2017        PMID: 31385967      PMCID: PMC6655395          DOI: 10.1093/nop/npw032

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  30 in total

1.  Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.

Authors:  Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

2.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

3.  Effect of disease burden on health-related quality of life in patients with malignant gliomas.

Authors:  D Osoba; M Brada; M D Prados; W K Yung
Journal:  Neuro Oncol       Date:  2000-10       Impact factor: 12.300

4.  Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.

Authors:  Vincent Caggiano; Richard V Weiss; Timothy S Rickert; Walter T Linde-Zwirble
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 6.  The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults.

Authors:  D L Silbergeld; R C Rostomily; E C Alvord
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

Review 7.  Management of venous thromboembolism in patients with primary and metastatic brain tumors.

Authors:  David E Gerber; Stuart A Grossman; Michael B Streiff
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

Review 8.  Impact of brain tumour treatment on quality of life.

Authors:  Jan J Heimans; Martin J B Taphoorn
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

9.  Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life.

Authors:  Martin Klein; Nadine H J Engelberts; Henk M van der Ploeg; Dorotheé G A Kasteleijn-Nolst Trenité; Neil K Aaronson; Martin J B Taphoorn; Hans Baaijen; W Peter Vandertop; Martin Muller; Tjeerd J Postma; Jan J Heimans
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

Review 10.  Quality of life in adults with brain tumors: current knowledge and future directions.

Authors:  Raymond Liu; Margaretta Page; Karla Solheim; Sherry Fox; Susan M Chang
Journal:  Neuro Oncol       Date:  2008-11-10       Impact factor: 12.300

View more
  1 in total

1.  Epilepsy education in gliomas: engaging patients and caregivers to improve care.

Authors:  Andrea Wasilewski; Jennifer Serventi; Chinazom Ibegbu; Thomas Wychowski; Joy Burke; Nimish Mohile
Journal:  Support Care Cancer       Date:  2019-07-02       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.